- Home
- JZXN vs SBFM Comparison
JZXN vs SBFM Comparison
Compare JZXN & SBFM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JZXN
- SBFM
- Stock Information
- Founded
- JZXN 2019
- SBFM 2006
- Country
- JZXN China
- SBFM United States
- Employees
- JZXN N/A
- SBFM N/A
- Industry
- JZXN Retail-Auto Dealers and Gas Stations
- SBFM Biotechnology: Pharmaceutical Preparations
- Sector
- JZXN Consumer Discretionary
- SBFM Health Care
- Exchange
- JZXN Nasdaq
- SBFM Nasdaq
- Market Cap
- JZXN N/A
- SBFM 4.9M
- IPO Year
- JZXN 2021
- SBFM N/A
- Fundamental
- Price
- JZXN $6.84
- SBFM $1.48
- Analyst Decision
- JZXN
- SBFM Strong Buy
- Analyst Count
- JZXN 0
- SBFM 1
- Target Price
- JZXN N/A
- SBFM $15.00
- AVG Volume (30 Days)
- JZXN 130.2K
- SBFM 3.7M
- Earning Date
- JZXN 05-19-2025
- SBFM 05-19-2025
- Dividend Yield
- JZXN N/A
- SBFM N/A
- EPS Growth
- JZXN N/A
- SBFM N/A
- EPS
- JZXN N/A
- SBFM N/A
- Revenue
- JZXN $1,400,139.00
- SBFM $34,874,283.00
- Revenue This Year
- JZXN N/A
- SBFM $192.48
- Revenue Next Year
- JZXN N/A
- SBFM N/A
- P/E Ratio
- JZXN N/A
- SBFM N/A
- Revenue Growth
- JZXN N/A
- SBFM 44.75
- 52 Week Low
- JZXN $1.00
- SBFM $1.19
- 52 Week High
- JZXN $6.83
- SBFM $91.40
- Technical
- Relative Strength Index (RSI)
- JZXN 69.48
- SBFM 36.43
- Support Level
- JZXN $6.00
- SBFM $1.17
- Resistance Level
- JZXN $7.20
- SBFM $1.65
- Average True Range (ATR)
- JZXN 0.95
- SBFM 0.31
- MACD
- JZXN 0.32
- SBFM -0.02
- Stochastic Oscillator
- JZXN 92.19
- SBFM 8.46
About SBFM Sunshine Biopharma Inc.
Sunshine Biopharma Inc is a pharmaceutical company offering and researching life-saving medicines in a wide variety of therapeutic areas, including oncology and antivirals. Through its subsidiaries, the company has various generic prescription drugs on the market in Canada and is also involved in developing and selling OTC supplements. In addition, the company is conducting a proprietary drug development program, which is comprised of K1.1 mRNA targeted for liver cancer and SBFM-PL4, PLpro protease inhibitor for SARS Coronavirus infections.